Loading company…
Predicta Med uses AI to support early detection and treatment selection for autoimmune diseases.
Founded in 2020 and based in Tel Aviv, Israel, Predicta Med develops PredictAI™, a decision support platform that analyzes health data to help providers identify and select treatments for autoimmune diseases, including Celiac, Crohn's Disease, and Multiple Sclerosis. In February 2023, the company raised venture funding from CerraCap Ventures to support growth and expansion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in